Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23839871 | 0.99 | GLP1R (0.52) | GLP1REPHX2ADRA1ANOD1EPOR | |
| SCHEMBL16638274 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL24891117 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL15357538 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL24890886 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL16947959 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL16638273 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL16947828 | 0.91 | GLP1R (0.67) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034928 | 0.91 | GLP1R (0.55) | GLP1REPHX2NOD1EPORITGB3 | |
| SCHEMBL19034958 | 0.91 | GLP1R (0.55) | GLP1REPHX2NOD1EPORITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | GLP1R, VIP, IAPP | GLP1R 1/4885EPHX2 2295/4885ADRA1A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.